Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)
Single Patient Emergency Treatment Use of Posaconazole in Invasive Fungal Infections
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT00686621, this observational or N/A phase trial focuses on Mycoses and remains ongoing. Sponsored by Merck Sharp & Dohme LLC, it has been updated 9 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)NCT00686621 was voluntarily registered even though it is a single patient use study, also known as compassionate exemption study; therefore results will not be disclosed for this study.
NCT00686621 was voluntarily registered even though it is a single patient use study, also known as compassionate exemption study; therefore results will not be disclosed for this study.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Approved For Marketing
-
Sep 2024 — Present [monthly]
Approved For Marketing
-
Jul 2024 — Sep 2024 [monthly]
Approved For Marketing
-
Jun 2022 — Jul 2024 [monthly]
Approved For Marketing
-
Jan 2021 — Jun 2022 [monthly]
Approved For Marketing
▶ Show 4 earlier versions
-
Jan 2019 — Jan 2021 [monthly]
Approved For Marketing
Status: Completed → Approved For Marketing · Phase: PHASE3 → None
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.